[1] Doll, R., Peto, R., Boreham, J. & Sutherland, I. Mortality from cancer in relation to smoking: 50 years observations on British doctors. Br. J. Cancer92, 426-429, doi:10.1038/sj.bjc.6602359 (2005).
[2] Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin.68, 394-424, doi:10.3322/caac.21492 (2018).
[3] Ferlay, J. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer127, 2893-2917, doi:10.1002/ijc.25516 (2010).
[4] Malik, P. S. & Raina, V. Lung cancer: prevalent trends & emerging concepts. Indian J. Med. Res.141, 5-7, doi:10.4103/0971-5916.154479 (2015).
[5] Thankappan, K. R. & Thresia, C. U. Tobacco use & social status in Kerala. Indian J. Med. Res.126, 300-308 (2007).
[6] Murray, C. J. & Lopez, A. D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet349, 1498-1504, doi:10.1016/S0140-6736(96)07492-2 (1997).
[7] Doll, R. & Hill, A. B. Smoking and carcinoma of the lung; preliminary report. Br. Med. J.2, 739-748, doi:10.1136/bmj.2.4682.739 (1950).
[8]] Ihsan, R. et al. Copy number polymorphism of glutathione-S-transferase genes (GSTM1 & GSTT1) in susceptibility to lung cancer in a high-risk population from north-east India. Indian J. Med. Res.139, 720-729 (2014).
[9] Ihsan, R. et al. Investigation on the role of p53 codon 72 polymorphism and interactions with tobacco, betel quid, and alcohol in susceptibility to cancers in a high-risk population from North East India. DNA Cell Biol.30, 163-171, doi:10.1089/dna.2010.1119 (2011).
[10] Behera, D. Epidemiology of lung cancer-Global and Indian perspective. J. Indian Acad. Clin. Med.13, 131-137 (2012).
[11] Behera, D. & Balamugesh, T. Lung cancer in India. Indian J. Chest Dis. Allied Sci.46, 269-281 (2004).
[12] Phukan, R. K. et al. Role of household exposure, dietary habits and glutathione S-Transferases M1, T1 polymorphisms in susceptibility to lung cancer among women in Mizoram India. Asian Pac. J. Cancer Prev.15, 3253-3260, doi:10.7314/apjcp.2014.15.7.3253 (2014).
[13] Kurmi, O. P., Arya, P. H., Lam, K. B., Sorahan, T. & Ayres, J. G. Lung cancer risk and solid fuel smoke exposure: a systematic review and meta-analysis. Eur. Respir. J.40, 1228-1237, doi:10.1183/09031936.00099511 (2012).
[14] Shen, H. et al. Global lung cancer risk from PAH exposure highly depends on emission sources and individual susceptibility. Sci. Rep.4, 6561, doi:10.1038/srep06561 (2014).
[15] Travis, W. D. Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod. Pathol.25 Suppl 1, S18-30, doi:10.1038/modpathol.2011.150 (2012).
[16] Doll, R. Mortality from lung cancer in asbestos workers. Br. J. Ind. Med.12, 81-86, doi:10.1136/oem.12.2.81 (1955).
[17] Cohen, A. J. Outdoor air pollution and lung cancer. Environ. Health Perspect.108 Suppl 4, 743-750, doi:10.1289/ehp.00108s4743 (2000).
[18] Loomis, D., Huang, W. & Chen, G. The International Agency for Research on Cancer (IARC) evaluation of the carcinogenicity of outdoor air pollution: focus on China. Chin. J. Cancer33, 189-196, doi:10.5732/cjc.014.10028 (2014).
[19]] Smolle, E. & Pichler, M. Non-Smoking-Associated Lung Cancer: A distinct Entity in Terms of Tumor Biology, Patient Characteristics and Impact of Hereditary Cancer Predisposition. Cancers (Basel)11, doi:10.3390/cancers11020204 (2019).
[20] Lan, Q. et al. Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat. Genet.44, 1330-1335, doi:10.1038/ng.2456 (2012).
[21] McKay, J. D. et al. Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes. Nat. Genet.49, 1126-1132, doi:10.1038/ng.3892 (2017).
[22] Dong, J. et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat. Genet.44, 895-899, doi:10.1038/ng.2351 (2012).
[23] Wang, Y. et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat. Genet.40, 1407-1409, doi:10.1038/ng.273 (2008).
[24] Bag, A., Bag, N., Jeena, L. M. & Jyala, N. S. Glutathione S-transferase T1 and myeloperoxidase -463 G>A genotypes in lung cancer patients of Kumaun region. J. Nat. Sci. Biol. Med.5, 293-296, doi:10.4103/0976-9668.136169 (2014).
[25] Bahl, C., Sharma, S., Singh, N. & Behera, D. Association study between genetic variations in Axin2 gene and lung cancer risk in North Indian population: A multiple interaction analysis. Tumour Biol.39, 1010428317695533, doi:10.1177/1010428317695533 (2017).
[26] Bahl, C., Singh, N., Behera, D. & Sharma, S. Association of polymorphisms in Dickopff (DKK) gene towards modulating risk for lung cancer in north Indians. Future Oncol.13, 213-232, doi:10.2217/fon-2016-0117 (2017).
[27] Bahl, C., Singh, N., Behera, D. & Sharma, S. High-order gene interactions between the genetic polymorphisms in Wnt and AhR pathway in modulating lung cancer susceptibility. Per. Med.14, 487-502, doi:10.2217/pme-2017-0018 (2017).
[28] Bahl, C., Singh, N., Behera, D. & Sharma, S. Genetic Variants in the Wingless Antagonist Genes (sFRP, DKK, and Axin2) Predict the Overall Survival and Prognosis of North Indian Lung Cancer Patients Treated with Platinum-Based Doublet Chemotherapy. Cancer Biother. Radiopharm., doi:10.1089/cbr.2018.2491 (2018).
[29 Lawania, S., Singh, N., Behera, D. & Sharma, S. Xeroderma pigmentosum complementation group D polymorphism toward lung cancer susceptibility survival and response in patients treated with platinum chemotherapy. Future Oncol.13, 2645-2665, doi:10.2217/fon-2017-0211 (2017).
[30] Natukula, K., Jamil, K., Pingali, U. R., Attili, V. S. & Madireddy, U. R. The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians. Asian Pac. J. Cancer Prev.14, 5275-5279, doi:10.7314/apjcp.2013.14.9.5275 (2013).
[31] Peddireddy, V. et al. Association of CYP1A1, GSTM1 and GSTT1 gene polymorphisms with risk of non-small cell lung cancer in Andhra Pradesh region of South India. Eur. J. Med. Res.21, 17, doi:10.1186/s40001-016-0209-x (2016).
[32] Peddireddy, V., Badabagni, S. P., Gundimeda, S. D. & Mundluru, H. P. Association of eNOS and ACE gene polymorphisms and plasma nitric oxide with risk of non-small cell lung cancer in South India. Clin. Respir. J.12, 207-217, doi:10.1111/crj.12517 (2018).
[33] Tilak, A. R., Kumar, S., Pant, M. C., Mathur, N. & Kumar, A. Polymorphism Arg72Pro of p53 confers susceptibility to squamous cell carcinoma of lungs in a North Indian population. DNA Cell Biol.32, 66-72, doi:10.1089/dna.2012.1792 (2013).
[34] Sobti, R. C., Sharma, S., Joshi, A., Jindal, S. K. & Janmeja, A. Genetic polymorphism of the CYP1A1, CYP2E1, GSTM1 and GSTT1 genes and lung cancer susceptibility in a north indian population. Mol. Cell. Biochem.266, 1-9, doi:10.1023/b:mcbi.0000049127.33458.87 (2004).
[35] Sreeja, L. et al. Possible risk modification by CYP1A1, GSTM1 and GSTT1 gene polymorphisms in lung cancer susceptibility in a South Indian population. J. Hum. Genet.50, 618-627, doi:10.1007/s10038-005-0303-3 (2005).
[36] Girdhar, Y., Singh, N., Behera, D. & Sharma, S. Synergistic association of CYP1A1 polymorphisms with increased susceptibility to squamous cell lung cancer in north Indian smokers. Int. J. Biol. Markers31, e402-e412, doi:10.5301/jbm.5000221 (2016).
[37] Naushad, S. M. et al. Population-level diversity in the association of genetic polymorphisms of one-carbon metabolism with breast cancer risk. J. Community Genet.7, 279-290, doi:10.1007/s12687-016-0277-1 (2016).
[38] Pradhan, S. et al. Indian genetic disease database. Nucleic Acids Res.39, D933-938, doi:10.1093/nar/gkq1025 (2011).
[39] Lee, Y. H. Meta-analysis of genetic association studies. Ann. Lab. Med.35, 283-287, doi:10.3343/alm.2015.35.3.283 (2015).
[40] Sengupta, D., Guha, U., Bhattacharjee, S. & Sengupta, M. Association of 12 polymorphic variants conferring genetic risk to lung cancer in Indian population: An extensive meta-analysis. Environ. Mol. Mutagen.58, 688-700, doi:10.1002/em.22149 (2017).
[41] Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ339, b2535, doi:10.1136/bmj.b2535 (2009).
[42] Huedo-Medina, T. B., Sanchez-Meca, J., Marin-Martinez, F. & Botella, J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol. Methods11, 193-206, doi:10.1037/1082-989X.11.2.193 (2006).
[43] W, V. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. 3, 1-48 (2010).
[44] Sengupta, D. et al. Meta-Analysis of Polymorphic Variants Conferring Genetic Risk to Cervical Cancer in Indian Women Supports CYP1A1 as an Important Associated Locus. Asian Pac. J. Cancer Prev.19, 2071-2081, doi:10.22034/APJCP.2018.19.8.2071 (2018).
[45] Martorell-Marugan, J., Toro-Dominguez, D., Alarcon-Riquelme, M. E. & Carmona-Saez, P. MetaGenyo: a web tool for meta-analysis of genetic association studies. BMC Bioinformatics18, 563, doi:10.1186/s12859-017-1990-4 (2017).
[46] Sterne, J. A. & Egger, M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol.54, 1046-1055, doi:10.1016/s0895-4356(01)00377-8 (2001).
[47] Liu, H. X., Li, J. & Ye, B. G. Correlation between gene polymorphisms of CYP1A1, GSTP1, ERCC2, XRCC1, and XRCC3 and susceptibility to lung cancer. Genet. Mol. Res.15, doi:10.4238/gmr15048813 (2016).
[48] Guengerich, F. P. & Shimada, T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res.400, 201-213, doi:10.1016/s0027-5107(98)00037-2 (1998).
[49] Parl, F. F. Glutathione S-transferase genotypes and cancer risk. Cancer Lett.221, 123-129, doi:10.1016/j.canlet.2004.06.016 (2005).
[50] Mao, B. & Niehrs, C. Kremen2 modulates Dickkopf2 activity during Wnt/LRP6 signaling. Gene302, 179-183, doi:10.1016/s0378-1119(02)01106-x (2003).
[51] Bao, J., Zheng, J. J. & Wu, D. The structural basis of DKK-mediated inhibition of Wnt/LRP signaling. Sci. Signal.5, pe22, doi:10.1126/scisignal.2003028 (2012).
[52] Zhu, J., Zhang, S., Gu, L. & Di, W. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Carcinogenesis33, 2334-2343, doi:10.1093/carcin/bgs278 (2012).
[53] Fatima, S., Luk, J. M., Poon, R. T. & Lee, N. P. Dysregulated expression of dickkopfs for potential detection of hepatocellular carcinoma. Expert. Rev. Mol. Diagn.14, 535-548, doi:10.1586/14737159.2014.915747 (2014).
[54] Hirata, H. et al. Wnt antagonist gene DKK2 is epigenetically silenced and inhibits renal cancer progression through apoptotic and cell cycle pathways. Clin.Cancer Res.15, 5678-5687, doi:10.1158/1078-0432.CCR-09-0558 (2009).
[55] Kawakita, A. et al. MicroRNA-21 promotes oral cancer invasion via the Wnt/beta-catenin pathway by targeting DKK2. Pathol. Oncol. Res.20, 253-261, doi:10.1007/s12253-013-9689-y (2014).
[56] Wang, Y. et al. miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression. Ann. Surg.264, 804-814, doi:10.1097/SLA.0000000000001928 (2016).
[57] Xu, W. et al. Dickkopf 2 promotes proliferation and invasion via Wnt signaling in prostate cancer. Mol. Med. Rep.14, 2283-2288, doi:10.3892/mmr.2016.5502 (2016).
[58] Hauer, K. et al. DKK2 mediates osteolysis, invasiveness, and metastatic spread in Ewing sarcoma. Cancer Res.73, 967-977, doi:10.1158/0008-5472.CAN-12-1492 (2013).
[59] Matsui, A. et al. DICKKOPF-4 and -2 genes are upregulated in human colorectal cancer. Cancer Sci.100, 1923-1930, doi:10.1111/j.1349-7006.2009.01272.x (2009).
[60] Min, J. K. et al. The WNT antagonist Dickkopf2 promotes angiogenesis in rodent and human endothelial cells. J. Clin. Invest.121, 1882-1893, doi:10.1172/JCI42556 (2011).
[61] Xiao, Q. et al. DKK2 imparts tumor immunity evasion through beta-catenin-independent suppression of cytotoxic immune-cell activation. Nat. Med.24, 262-270, doi:10.1038/nm.4496 (2018).
[62] Shen, T., Chen, Z., Qiao, J., Sun, X. & Xiao, Q. Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells. Cell Death Discov.5, 123, doi:10.1038/s41420-019-0204-4 (2019).
[63] Chen, L., Zhuo, D., Chen, J. & Yuan, H. XRCC1 polymorphisms and lung cancer risk in Caucasian populations: a meta-analysis. Int. J. Clin. Exp. Med.8, 14969-14976 (2015).
[64] Guo, S. et al. The relationship between XRCC1 and XRCC3 gene polymorphisms and lung cancer risk in northeastern Chinese. PLoS One8, e56213, doi:10.1371/journal.pone.0056213 (2013).
[65] Kiyohara, C., Takayama, K. & Nakanishi, Y. Lung cancer risk and genetic polymorphisms in DNA repair pathways: a meta-analysis. J. Nucleic Acids2010, 701760, doi:10.4061/2010/701760 (2010).
[66] Qian, B. et al. Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer73, 138-146, doi:10.1016/j.lungcan.2010.11.018 (2011).
[67] Gao, W. M. et al. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer. Carcinogenesis24, 1671-1676, doi:10.1093/carcin/bgg115 (2003).
[68] Hou, S. M. et al. Influence of common XPD and XRCC1 variant alleles on p53 mutations in lung tumors. Environ. Mol. Mutagen.41, 37-42, doi:10.1002/em.10128 (2003).
[69] Kiyohara, C., Takayama, K. & Nakanishi, Y. Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis. Lung Cancer54, 267-283, doi:10.1016/j.lungcan.2006.08.009 (2006).
[70] Li, Y. et al. Assessment of the association between XRCC1 Arg399Gln polymorphism and lung cancer in Chinese. Tumour Biol.34, 3681-3685, doi:10.1007/s13277-013-0950-5 (2013).
[71] Zheng, H., Wang, Z., Shi, X. & Wang, Z. XRCC1 polymorphisms and lung cancer risk in Chinese populations: a meta-analysis. Lung Cancer65, 268-273, doi:10.1016/j.lungcan.2009.02.002 (2009).
[72] Moorjani, P. et al. Genetic evidence for recent population mixture in India. Am. J. Hum. Genet.93, 422-438, doi:10.1016/j.ajhg.2013.07.006 (2013).
[73] Ji, Y. N., Wang, Q. & Suo, L. J. CYP1A1 Ile462Val polymorphism contributes to lung cancer susceptibility among lung squamous carcinoma and smokers: a meta-analysis. PLoS One7, e43397, doi:10.1371/journal.pone.0043397 (2012).
[74] Kiyohara, C., Horiuchi, T., Takayama, K. & Nakanishi, Y. Genetic polymorphisms involved in carcinogen metabolism and DNA repair and lung cancer risk in a Japanese population. J. Thorac. Oncol.7, 954-962, doi:10.1097/JTO.0b013e31824de30f (2012).
[75] Kim, I. S. et al. Polymorphisms and haplotypes in the XRCC1 gene and the risk of advanced non-small cell lung cancer. J. Thorac. Oncol.5, 1912-1921, doi:10.1097/JTO.0b013e3181f46708 (2010).
[76] Yin, J., Vogel, U., Ma, Y., Qi, R. & Wang, H. Haplotypes of nine single nucleotide polymorphisms on chromosome 19q13.2-3 associated with susceptibility of lung cancer in a Chinese population. Mutat. Res.641, 12-18, doi:10.1016/j.mrfmmm.2008.02.004 (2008).
[77] Chang, J. S. et al. Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans. Carcinogenesis30, 78-87, doi:10.1093/carcin/bgn261 (2009).
[78] Ihsan, R. et al. Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One6, e29431, doi:10.1371/journal.pone.0029431 (2011).
[79] Islam, M. S. et al. Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clin. Chim. Acta416, 11-19, doi:10.1016/j.cca.2012.11.011 (2013).